COX-2 inhibitors for cancer treatment in dogs

Pakistan Veterinary Journal

Volumn 31, Issue 4, 2011, Pages 275-279

  De Nardi, Andrigo Barboza ^a   Raposo, Talita Mariana Morata ^b   Huppes, Rafael Ricardo ^b   Daleck, Carlos Roberto ^b   Amorim, Renée Laufer ^b  

^a UNIVERSIDADE DE FRANCA   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Canine; Coxibs; Cyclooxygenase 2; Tumor

Indexed keywords

EID: 83755184105     PISSN: 02538318     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Arber N, 2008. Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point. Cancer Epidem Biomarker Prev, 17: 1852-1857.
2. Bakhle YS, 2001. Cox-2 and cancer: a new approach to an old problem. Br J Pharmacol, 134: 1137-1150.
3. Bol DK, B Rowley, CP Ho, B Pilz, M Swerdel, K Kiguchi, S Muga, R Klein and M Fischer, 2002. Cyclooxygenase 2 overexpression in the skin of transgenic mice results in suppression of tumor development. Cancer Res, 62: 2516-2521.
4. Borzacchiello G, V Russo and M Russo, 2007. Immunohistochemical expression of cyclooxygenase- 2 in canine ovarian carcinomas. J Vet Med A Physiol Pathol Clin Med, 54: 247-249.
5. Cao Y and SM Prescott, 2002. Many actions of cyclooxigenase-2 in cellular dynamics and in cancer. J Cell Physiol, 190: 279-286.
6. Chun R and DH Thamm, 2007. Targeting angiogenesis and tumor vasculature. In: Small Animal Clinical Oncology (Withrow SJ, MacEwen EG, eds). 4th Ed, WB Saunders, St Louis, USA, pp: 259-265.
7. Dannenberg AJ, NK Altorki, JO Boyle, C Dang, LR Howe and BB Weksler, 2001. Cyclooxygenase-2: a pharmacological target for the prevention of cancer. Lancet Oncol, 2: 544-551.
8. Davies NM, 1995. Toxicity of nonsteroidal antiinflammatory drugs in the large intestine. Dis Colon Rectum, 38: 1311-1321.
9. De Nardi AB, S Rodaski, NS Rocha and SC Fernandes, 2009. Neoplasias Mamárias. In: Oncologia em Cães e Gatos (Daleck CR, De Nardi AB, Rodaski S, eds): Roca, São Paulo, Brasil, pp: 371-384.
10. De Nardi AB, CR Daleck, RL Amorin, S Rodaski, C Calderon, R Torres Neto and AU Malaver, 2007. Immunoexpression of cyclooxygenase-2 in mammary neoplasia in dogs. Selecciones Vet, 15: 9-13.
11. Denkert C, KJ Winzer, BM Müller, W Weichert, S Pest, M Köbel, G Kristiansen, A Reles, A Siegert, H Guski and S Hauptmann, 2003. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer, 97: 2978-2987.
12. Dias Pereira P, CC Lopes, AJ Matos, M Santos, F Gartner, R Medeiros and C Lopes, 2009. COX-2 expression in canine normal and neoplastic mammary gland. J Comp Pathol, 140: 247-253.
13. Dong M, K Gouda, PR Nambiar, A Resaie, GS Belinsky, G Lambeau, C Giardina and DW Rosemberg, 2003. Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis. J Carcinog, 24: 307-315.
14. Doré M, I Lanthier and J Sirois, 2003. Cyclooxygenase-2 expression in canine mammary tumors. Vet Pathol, 40: 207-212.
15. Dvory-Sobol H and N Arber, 2007. Cyclooxygenase-2 as target for chemopreventive interventions: new approaches. Cancer Biomark, 3: 153-161.
16. Eberhat CE, RJ Coffey, A Radhika, FM Giardello, S Ferrenbach and RN Dubois, 1994. Up-regulation of cyclooxygenase 2 gene expression in human collateral adenomas and adenocarcinomas. Gastroenterol, 107: 1183-1188.
17. Heller DA, CA Clifford, MH Goldschmidt, DE Holt, MJ Manfredi and KU Sorenmo, 2005. Assessment of cyclooxygenase-2 expression in canine hemangiosarcoma, histiocytic sarcoma, and mast cell tumor. Vet Pathol, 42: 350-353.
18. Hida T, Y Yatabe, H Achiwa, H Muramatsu, K Kozabi, S Nakamura, M Ogawa, T Mitsudomi, T Sugiura and T Takahashi, 1998. Increased expressed of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res, 58: 3761-3764.
19. Howe LR, 2007. Cyclooxygenase and prostaglandin signaling and breast cancer. Breast Cancer Res, 9: 1-9.
20. Impellizeri JA and DG Esplin, 2008. Expression of cyclooxygenase-2 in canine nasal carcinomas. Vet J, 176: 408-410.
21. Jones CJ and SC Budsberg, 2000. Physiologic characteristics and clinical importance of the cyclooxygenase isoforms in dogs and cats. J Am Vet Med Assoc, 217: 721-729.
22. Kawamori T, CV Rao, K Seibert and BS Reddy, 1998. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res, 58: 409-412.
23. Knapp DW, RC Richardson, GD Bottoms, R Teclaw and TCK Chan, 1992. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother Pharmacol, 29: 214-218.
24. Knapp DW, RC Richardson, TC Chan, GD Bottms, WR Widmer, DB De Nicola, R Teclaw, PL Bonney and T Kuczekt, 1994. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med, 8: 273-278.
25. Knottenbelt CM, JW Simpson, S Tasker, AE Ridyard, ML Chandler, PM Jamieson and EM Welsh, 2000. Preliminary clinical observations on the use of piroxicam in the management of rectal tubulopapillary polyps. J Small Anim Pract, 41: 393-397.
26. Knottenbelt C, D Mellor, C Nixon, H Thompson and DJ Argyle, 2006. Cohort study of COX-1 and COX-2 expression in canine rectal and bladder tumors. J Small Anim Pract, 47: 196-200.
27. L'Eplattenier HF, CL Lai, R Van den ham, J Mol, F Van Sluijs and E Tesk, 2007. Regulation of COX-2 expression in canine prostate carcinoma: increased COX-2 expression is not related to inflammation. J Vet Inter Med, 21: 776-782.
28. Lascelles BDX, 2007. Supportive Care for the Cancer Patient. In: Small Animal Clinical Oncology (Withrow SJ and EG MacEwen, eds). 4th Ed, WB Saunders, St. Louis, USA, pp: 291-306.
29. Lavalle GE, AC Bertagnolli, WLF Tavares and GD Cassali, 2009. Cox-2 Expression in Canine Mammary Carcinomas: Correlation with Angiogenesis and Overall Survival. Vet Pathol, 46: 1275-1280.
30. León-Artozqui M and A Morcate, 2008. Progresos en el tratamiento del dolor con Previcox (firocoxibe): historia y datos clínicos. Consultation, 16: 41-45.
31. Mcentee MF, JM Cates and N Neilsen, 2002. Cyclooxygenase-2 expression in spontaneous intestinal neoplasia of domestic dogs. Vet Pathol, 39: 428-436.
32. Millanta, F, S Citi, D Della Santa, M Porciani and A Poli, 2006: Cox-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic molecular markers. Breast Cancer Res Treat, 98: 115-120.
33. Mohammed SI, BA Craig, AJ Mutsaers, NW Glickman, PW Snyder, De AE Gortari, DL Schlittler, KT Coffman, PL Bonney and DW Knapp, 2003. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Mol Cancer Ther, 2: 183-188.
34. Mohammed SI, KNM Khan, RS Sellers, MG Hayek, DB DeNicola, L Wu, PL Bonney and DW Knapp, 2004. Expression of cyclooxygenase-1 and 2 in naturally occurring canine cancer. Prostaglandins Leukot Essent Fatty Acids, 70: 479-483.
35. Mohammed SI, K Coffman, NW Glickman, MG Hayek, DJ Waters, D Schlittler, DB DeNicola and DW Knapp, 2001. Prostaglandin E2 concentretions in naturally occurring canine cancer. Prostaglandins, Leukot Essent Fatty Acids, 64: 1-4.
36. Mullins MN, SE Lana, WS Dernell, GK Ogilvie, SJ Withrow and EJ Ehrhart, 2004. Cyclooxygenase-2 expression in canine appendicular osteosarcomas. J Vet Inter Med, 18: 859-865.
37. Murray MD and DC Brater, 1993. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu Rev Pharmacol Toxicol, 32: 435-467.
38. Mutsaers AJ, SI Mohammed, DB DeNicola, PW Snyder, MW Glickman, PF Bennett, AE De Gortari, PL Bonney and DW Knapp, 2005. Pretreatment tumor prostaglandin E2 concentration and cyclooxygenase-2 expression are not associated with the response of canine naturally occurring invasive urinary bladder cancer to cyclooxygenase inhibitor therapy. Prostaglandins Leukot Essent Fatty Acids, 72: 181-186.
39. Oshima M, JE Dinchuk, SL Kargman, H Oshima, B Hancock, E Kwong, JM Trazskos, JF Evans and MM Taketo, 1996. Suppression of intestinal polyposis in Apc_716 knockout mice by inhibition of cyclooxygenase-2. Cell, 87: 803-809.
40. Pires I, A Garcia, J Prada and FL Queiroga, 2010. COX-1 and COX-2 expression in canine cutaneous, oral and ocular melanocytic tumours. J Comp Path, 143: 142-149.
41. Queiroga FL, MD Perez-alenza, G Silvan, L Pena, C Lopes and JC Illera, 2005. Cox-2 levels in canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance. Antican Res, 25: 4269-4275.
42. Queiroga FL, A Alves, I Pires and C Lopes, 2007. Expression of cox-1 and cox-2 in canine mammary tumours. J Comp Pathol, 136: 177-185.
43. Queiroga FL, I Pires, L Lobo and CS Lopes. 2010. The role of Cox-2 expression in the prognosis of dogs with malignant mammary tumours. Res Vet Scienc, 88: 441-445.
44. Rodaski S and CH Piekarz, 2009. Epidemiologia e Etiologia do Câncer. In: Oncologia em Cães e Gatos (Daleck CR, De Nardi AB, Rodaski S, eds): Roca, São Paulo, Brasil, pp: 1-22.
45. Rossmeisl Junior JH, JL Robertson, KL Zimmerman, MA Higgins and DA Geiger, 2009. Cyclooxygenase-2 (COX-2) expression in canine intracranial meningiomas. Vet Comp Oncol, 7: 173-80.
46. Souza CHM, E Toledo-Piza, RL Amorin, AB De Nardi and KM Tobias, 2009. Inflammatory mammary carcinoma in 12 dogs: Clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment. Can Vet J, 50: 506-510.
47. Spugnini EP, A Porrello, G Citro and A Baldi, 2005. COX-2 overexpression in canine tumors: potential therapeutic targets in oncology. Histol Histopathol, 20: 1309-1312.
48. Subbaramaiah K, N Telang, JT Ramonetti, R Araki, B Devito, BB Weksler and AJ Dannenberg, 1996. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res, 54: 4424-4429.
49. Surh YJ, KS Chun, HH Cha, SS Han, SY Keum, KK Park and SS Lee, 2001. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phyochemicals: down-regulation of COX-2 and iNOS through supression of NF-kB activation. Mutation Res, 480-481: 243-268.
50. Thun MJ, SJ Henley and C Patrono, 1993. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues. J Nat Cancer Instit, 94: 252-266.
51. Wang LS, YW Huang, S Liu, HL Chang, W Ye, S Shu, Y Sugimoto, JA Funk, DD Smeaks, LN Hill and YC Lin, 2006. Conjugated linoleic acid (CLA) modulates prostaglandin E2 (PGE2) signaling in canine mammary cells. Anticancer Res, 26: 889-898.
52. Wolfesberger B, I Walter, C Hoelzl, JG Thalhammer and M Egerbacher, 2006. Antineoplastic effect of the cyclooxygenase inhibitor meloxicam on canine osteosarcoma cells. Res Vet Sci, 80: 308-316.
53. Zha S, WR Gage, J Sauvageot, EA Saria, MJ Putzi, CM Ewing, DA Faith, WG Nelson, AM Demarzo and WB Isaacs, 2001. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res, 61: 8617-8623.